amicus therapeutics inc. - FOLD
FOLD
Close Chg Chg %
9.87 0.15 1.47%
Open Market
10.02
+0.15 (1.47%)
Volume: 615.64K
Last Updated:
Nov 27, 2024, 2:40 PM EDT
Company Overview: amicus therapeutics inc. - FOLD
FOLD Key Data
| Open $9.87 | Day Range 9.81 - 10.07 |
| 52 Week Range 9.02 - 14.57 | Market Cap $2.95B |
| Shares Outstanding 298.81M | Public Float 291.20M |
| Beta 0.67 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.35 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.47M |
FOLD Performance
| 1 Week | 2.17% | ||
| 1 Month | -15.57% | ||
| 3 Months | -14.99% | ||
| 1 Year | -12.03% | ||
| 5 Years | -5.82% |
FOLD Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
13
Full Ratings ➔
About amicus therapeutics inc. - FOLD
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
FOLD At a Glance
Amicus Therapeutics, Inc.
47 Hulfish Street
Princeton, New Jersey 08542
| Phone | 1-609-662-2000 | Revenue | 399.36M | |
| Industry | Pharmaceuticals: Major | Net Income | -151,584,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 21.299% | |
| Fiscal Year-end | 12 / 2024 | Employees | 517 | |
| View SEC Filings |
FOLD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 10.488 |
| Price to Book Ratio | 26.01 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -66.248 |
| Enterprise Value to Sales | 10.886 |
| Total Debt to Enterprise Value | 0.102 |
FOLD Efficiency
| Revenue/Employee | 772,448.743 |
| Income Per Employee | -293,199.226 |
| Receivables Turnover | 4.557 |
| Total Asset Turnover | 0.532 |
FOLD Liquidity
| Current Ratio | 2.881 |
| Quick Ratio | 2.525 |
| Cash Ratio | 1.707 |
FOLD Profitability
| Gross Margin | 88.682 |
| Operating Margin | -18.403 |
| Pretax Margin | -37.586 |
| Net Margin | -37.957 |
| Return on Assets | -20.184 |
| Return on Equity | -107.043 |
| Return on Total Capital | -25.046 |
| Return on Invested Capital | -26.056 |
FOLD Capital Structure
| Total Debt to Total Equity | 277.86 |
| Total Debt to Total Capital | 73.535 |
| Total Debt to Total Assets | 57.214 |
| Long-Term Debt to Equity | 272.663 |
| Long-Term Debt to Total Capital | 72.16 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Amicus Therapeutics Inc. - FOLD
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 260.89M | 305.51M | 329.23M | 399.36M | |
Sales Growth
| +43.16% | +17.11% | +7.76% | +21.30% | |
Cost of Goods Sold (COGS) incl D&A
| 39.89M | 40.67M | 43.94M | 45.20M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 8.85M | 6.21M | 5.34M | 7.87M | |
Depreciation
| 8.85M | 6.21M | 5.34M | 5.37M | |
Amortization of Intangibles
| - | - | - | 2.50M | - |
COGS Growth
| +49.19% | +1.97% | +8.03% | +2.86% | |
Gross Income
| 221.00M | 264.84M | 285.29M | 354.16M | |
Gross Income Growth
| +42.12% | +19.84% | +7.72% | +24.14% | |
Gross Profit Margin
| +84.71% | +86.69% | +86.65% | +88.68% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 464.85M | 464.76M | 489.72M | 427.65M | |
Research & Development
| 308.44M | 272.05M | 276.68M | 152.38M | |
Other SG&A
| 156.41M | 192.71M | 213.04M | 275.27M | |
SGA Growth
| +1.89% | -0.02% | +5.37% | -12.67% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 10.42M | (166.63M) | 7.69M | 17.65M | |
EBIT after Unusual Expense
| (254.27M) | (33.29M) | (212.12M) | (91.14M) | |
Non Operating Income/Expense
| 2.44M | (175.79M) | 7.20M | (8.81M) | |
Non-Operating Interest Income
| 3.23M | 509.00K | 3.02M | 7.08M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 22.43M | 32.47M | 37.12M | 50.15M | |
Interest Expense Growth
| +18.83% | +44.80% | +14.31% | +35.10% | |
Gross Interest Expense
| 22.43M | 32.47M | 37.12M | 50.15M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (274.25M) | (241.55M) | (242.04M) | (150.10M) | |
Pretax Income Growth
| +22.94% | +11.92% | -0.20% | +37.98% | |
Pretax Margin
| -105.12% | -79.06% | -73.52% | -37.59% | |
Income Tax
| 2.60M | 8.91M | (5.47M) | 1.48M | |
Income Tax - Current - Domestic
| - | - | 6.00K | 14.00K | - |
Income Tax - Current - Foreign
| 4.16M | 8.86M | (5.76M) | 6.41M | |
Income Tax - Deferred - Domestic
| (1.56M) | 49.00K | 283.00K | (4.94M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (276.85M) | (250.46M) | (236.57M) | (151.58M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (276.85M) | (250.46M) | (236.57M) | (151.58M) | |
Net Income Growth
| +22.32% | +9.53% | +5.55% | +35.92% | |
Net Margin Growth
| -106.12% | -81.98% | -71.85% | -37.96% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (276.85M) | (250.46M) | (236.57M) | (151.58M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (276.85M) | (250.46M) | (236.57M) | (151.58M) | |
EPS (Basic)
| -1.0695 | -0.9228 | -0.8184 | -0.5136 | |
EPS (Basic) Growth
| +27.85% | +13.72% | +11.31% | +37.24% | |
Basic Shares Outstanding
| 258.87M | 271.42M | 289.06M | 295.16M | |
EPS (Diluted)
| -1.0695 | -0.9228 | -0.8184 | -0.5136 | |
EPS (Diluted) Growth
| +27.85% | +13.72% | +11.31% | +37.24% | |
Diluted Shares Outstanding
| 258.87M | 271.42M | 289.06M | 295.16M | |
EBITDA
| (235.01M) | (193.71M) | (199.08M) | (65.62M) | |
EBITDA Growth
| +20.60% | +17.57% | -2.77% | +67.04% | |
EBITDA Margin
| -90.08% | -63.40% | -60.47% | -16.43% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 17.667 | |
| Number of Ratings | 13 | Current Quarters Estimate | 0.018 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -0.199 | |
| Last Quarter’s Earnings | -0.02 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.51 | Next Fiscal Year Estimate | 0.146 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 10 | 7 | 10 | 10 |
| Mean Estimate | 0.02 | -0.00 | -0.20 | 0.15 |
| High Estimates | 0.06 | 0.06 | -0.11 | 0.35 |
| Low Estimate | -0.03 | -0.05 | -0.26 | 0.02 |
| Coefficient of Variance | 154.66 | -1,504.30 | -23.03 | 71.36 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 11 | 11 | 10 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 2 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Amicus Therapeutics Inc. - FOLD
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Amicus Therapeutics Inc. - FOLD
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 8, 2024 | Bradley Lewis Campbell President and CEO; Director | 894,555 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $12.28 per share | 10,985,135.40 |
| Nov 8, 2024 | Bradley Lewis Campbell President and CEO; Director | 886,654 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.5 per share | 11,083,175.00 |
| Nov 8, 2024 | Bradley Lewis Campbell President and CEO; Director | 67,100 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Apr 17, 2024 | Samantha Lynn Prout Chief Accounting Officer | 73,926 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $10.66 per share | 788,051.16 |
| Mar 18, 2024 | John Francis Crowley Executive Chairman; Director | 958,627 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.65 per share | 13,085,258.55 |
| Mar 18, 2024 | Ellen Stacy Rosenberg Chief Legal Officer | 396,219 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 18, 2024 | David M. Clark Chief People Officer | 280,389 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 18, 2024 | David M. Clark Chief People Officer | 271,775 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.65 per share | 3,709,728.75 |
| Mar 18, 2024 | Jeffrey P. Castelli Chief Development Officer | 377,205 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.65 per share | 5,148,848.25 |
| Mar 18, 2024 | Jeffrey P. Castelli Chief Development Officer | 387,210 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 18, 2024 | Ellen Stacy Rosenberg Chief Legal Officer | 384,219 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.65 per share | 5,244,589.35 |
| Mar 18, 2024 | John Francis Crowley Executive Chairman; Director | 927,013 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.65 per share | 12,653,727.45 |
| Mar 18, 2024 | John Francis Crowley Executive Chairman; Director | 995,492 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 12, 2024 | Glenn P. Sblendorio Director | 83,596 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.8 per share | 234,068.80 |
| Mar 12, 2024 | Glenn P. Sblendorio Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 7, 2024 | Margaret G. McGlynn Director | 66,789 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.8 per share | 187,009.20 |
| Mar 7, 2024 | Margaret G. McGlynn Director | 59,289 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.29 per share | 787,950.81 |
| Mar 7, 2024 | Margaret G. McGlynn Director | 66,789 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $2.8 per share | 187,009.20 |
| Mar 7, 2024 | Margaret G. McGlynn Director | 59,289 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.4 per share | 794,472.60 |
| Mar 7, 2024 | Margaret G. McGlynn Director | 7,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |